The Texas Medical Center Library

DigitalCommons@TMC
The University of Texas MD Anderson Cancer
Center UTHealth Graduate School of
Biomedical Sciences Dissertations and Theses
(Open Access)

The University of Texas MD Anderson Cancer
Center UTHealth Graduate School of
Biomedical Sciences

12-2017

CHARACTERIZATION OF NOTCH1 AND PI3K-PTEN-AKT/mTOR
PATHWAY INTERACTION IN HEAD AND NECK SQUAMOUS CELL
CARCINOMA
Kyriante' Henry

Follow this and additional works at: https://digitalcommons.library.tmc.edu/utgsbs_dissertations
Part of the Biology Commons, Cancer Biology Commons, Cell Biology Commons, Laboratory and
Basic Science Research Commons, and the Molecular Biology Commons

Recommended Citation
Henry, Kyriante', "CHARACTERIZATION OF NOTCH1 AND PI3K-PTEN-AKT/mTOR PATHWAY INTERACTION
IN HEAD AND NECK SQUAMOUS CELL CARCINOMA" (2017). The University of Texas MD Anderson
Cancer Center UTHealth Graduate School of Biomedical Sciences Dissertations and Theses (Open
Access). 824.
https://digitalcommons.library.tmc.edu/utgsbs_dissertations/824

This Thesis (MS) is brought to you for free and open
access by the The University of Texas MD Anderson
Cancer Center UTHealth Graduate School of Biomedical
Sciences at DigitalCommons@TMC. It has been
accepted for inclusion in The University of Texas MD
Anderson Cancer Center UTHealth Graduate School of
Biomedical Sciences Dissertations and Theses (Open
Access) by an authorized administrator of
DigitalCommons@TMC. For more information, please
contact digitalcommons@library.tmc.edu.

CHARACTERIZATION OF NOTCH1 AND PI3K-PTEN-AKT/mTOR PATHWAY
INTERACTION IN HEAD AND NECK SQUAMOUS CELL CARCINOMA
by
Kyriante’ Savonn Henry, B.S.

APPROVED:

_______________________________________
Faye M. Johnson, M.D., Ph.D.
Advisory Professor

_______________________________________
Michael A. Davies, M.D., Ph.D.

_______________________________________
Mitchell J. Frederick, Ph.D.

_______________________________________
Gordon B. Mills, M.D., Ph.D.

_______________________________________
Andrew J. Bean, Ph.D.

APPROVED:

_______________________________________
Dean, The University of Texas
MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences

CHARACTERIZATION OF NOTCH1 AND PI3K-PTEN-AKT/mTOR PATHWAY
INTERACTION IN HEAD AND NECK SQUAMOUS CELL CARCINOMA

A

THESIS

Presented to the Faculty of
The University of Texas
MD Anderson Cancer Center
UTHealth Graduate School of Biomedical Sciences
in Partial Fulfillment
of the Requirements
of the Degree of

MASTER OF SCIENCE

By

Kyriante’ Savonn Henry, B.S.
Houston, Texas
December 2017

Dedication
First and foremost, I would like to thank my Lord and Savior, Jesus Christ, for
blessing me with the opportunity to complete my scientific studies at such a prestigious
institution as The University of Texas MD Anderson Cancer Center UTHealth Graduate
School of Biomedical Sciences. Though the journey was challenging and arduous, I am
proud to say that I successfully completed my thesis project because of the grace and
mercy of my Heavenly Father. After all, “I can do all things through Christ who
strengthens me (Philippians 4:13).”
This thesis is dedicated to all of the people who have loved and encouraged me
as I worked to complete my thesis project during the past two years, and those who
continue to support me as I embark on future endeavors in my scientific career.
To my grandparents, Nell Duncan, Alice Duncan, Mary Henry, Louis Henry, Jr.,
Wayne Bartholomew, and Lloyd Bourgeois: I thank each of you for nurturing me with the
love, care, and guidance that I needed to believe in myself and become who I was
destined to be.
To my mother, Kione Duncan: Thank you for giving me life and being the push
that I needed to persevere. You mean more to me than words can express.
To my siblings, Kodie, Koby, Tyler, Lil Man, and Imani: Thank you for holding me
accountable for every word, deed, and action. Being the oldest of you all, I pray that I
continue to be an exemplar role model for each and every one of you. Through all of the
trials and tribulations that life may bring, you must stop at nothing to achieve your dreams
and accomplish your goals. It is through discipline, hard work, perseverance, and
confidence in yourself that you will prevail. When the road gets that much tougher, know
that I’ll be there to help guide each of you along the way.

iii

To my step-mother, Cocoa Green, and my godfather, Odel McKnight: Thank you
both for always being there to cheer me along and always being there for me when I
needed you. I am forever grateful to the both of you.
To my boyfriend, Walter Peterson, Jr.: Thank you for being my support system,
always there to encourage and uplift me when I needed it most. Thank you for every
clean dish, every folded article of laundry, and every cooked meal. Thank you for taking
care of my well-being when I was too tired and frustrated from the lab to take care of
myself.
To my guardian Angels, A’nara, LaTanya, and Mary Henry: Thank you for
constantly guiding me, watching over me, and protecting me. I know that you all are
fighting the battles for me that I cannot fight for myself. I feel your presence all the time
and I pray that I am making you proud. Though it took you all from this life too soon, I
promise you that one day very soon we will eradicate the menace that is cancer. This
thesis is a genuine dedication to you all!
Last, but certainly not least, to my twin, my backbone, my Daddy, Louis Henry,
Sr.: Words cannot even begin to express how much you truly mean to me. Thank you for
being my biggest critic and my biggest cheerleader, always giving me the strength and
confidence that I needed to keep going when I was ready to give up. With your
unconditional love and guidance, I know that I can achieve the unthinkable. I am who I
am because of who you are. Thank you for instilling in your Princess the morals and
values that I needed to succeed in this world. You are truly a blessing to my life, the best
father a daughter can ask for. This is only the beginning of the Henry Empire. TEAM
HENRY FOREVER!
Again, thank you to all of my friends and family members of the Henry, Duncan,
and Bourgeois families! I love you all very much!!!
iv

Acknowledgments
I would like to express my sincerest gratitude to my mentor, Dr. Faye M. Johnson,
for granting me the opportunity to complete my thesis project in her lab and helping me
to develop my abilities as a scientist. I would also like to acknowledge and thank the
current and former members of my lab for the significant contributions they have made
to my research and my overall lab experience: Drs. Tuhina Mazumdar, Shaohua Peng,
Ratnakar Singh, Guobin Fu, and Hongyun “Jane” Zhao, as well as Pavitra Viswanath
and Geneva Williams. A huge thank you to Drs. Nene Kalu and Vaishnavi Sambandam
for being there every step of the way to help me with my project. Because of you guys,
my issues with western blotting and qRT-PCR are a thing of the past! Thank you all very
much!
Additionally, I would like to thank my advisory committee members (Drs. Michael
A. Davies, Mitchell J. Frederick, Gordon B. Mills, and Andrew J. Bean) for their guidance
and support in helping me to cultivate and complete a thesis project that would improve
our efforts in developing targeted therapies to treat various cancer types.
Lastly, I would like to extend my greatest appreciation to the faculty and staff of
the GSBS academic offices, especially Brenda Gaughan and Drs. Andy Bean, Marenda
Wilson-Pham, and Lindsey Minter. Thank you all for being a “home away from home” for
me and for creating a safe-haven, where I could go to vent and obtain peace without
being judged. Thank you all for being there to advise and guide me during my academic
tenure at GSBS. If it were not for your encouragement, I would not have made it. I am
grateful for you all!

v

CHARACTERIZATION OF NOTCH1 AND PI3K-PTEN-AKT/mTOR PATHWAY
INTERACTION IN HEAD AND NECK SQUAMOUS CELL CARCINOMA

Kyriante’ Savonn Henry, B.S.

Advisory Professor: Faye M. Johnson, M.D., Ph.D.

Head and neck squamous cell carcinoma (HNSCC) affects various mucosal sites
of the upper aerodigestive tract, including the nasal and oral cavities, the nasopharynx,
and the oropharynx. More than five hundred thousand new cases of HNSCC occurred in
2011 alone, with 50,000 reported cases in the United States. This trend made HNSCC
the seventh most common non-skin cancer worldwide (Ferlay et al., 2015). Although
significant epidemiological and pathological advancements have been made, survival
rates have not improved much over the last 40 years, leaving a mortality rate that remains
at approximately 50%. An unbiased drug screen demonstrated that HNSCC cell lines
bearing NOTCH1 inactivating mutations are sensitive to PI3K and dual PI3K/mTOR
inhibitors, leading us to investigate the interaction of these pathways in HNSCC. The
NOTCH pathway plays key roles in cell proliferation, differentiation, and apoptosis. With
inactivating mutations in 18% of 510 HNSCC patient samples, NOTCH1 is one of the
most frequently altered genes in HNSCC (TCGA, Provisional). In 21 patients with
HNSCC tumors, approximately 28 NOTCH1 mutations predicted tumor suppressive
properties (Agrawal et al., 2011). The PI3K/mTOR pathway is a critical regulator of cell
growth, proliferation, differentiation, and survival. It is the most frequently altered
pathway in HNSCC, occurring in approximately 80% of HNSCC tumors (IglesiasBartolome R, et al., 2013). Previous research suggests that NOTCH1 regulates PI3Kvi

AKT and mTOR1 signaling in T-ALL cells by decreasing PTEN expression. In addition,
blocking NOTCH1 activity has been shown to upregulate PTEN activity in T-ALL cells via
Hes1 downregulation (Palomero T, et al., 2007). Unfortunately, the mechanism of
communication between the two pathways is unknown in HNSCC. Understanding the
interaction between the NOTCH1 and PI3K/AKT/mTOR signaling pathways presents
them as essential targeting agents that may have a significant impact on modern
therapeutic medicine. In this research, we sought to investigate whether the NOTCH1
pathway regulates the activity of the PI3K-PTEN-AKT/mTOR pathway in HNSCC in vitro.
The data of various experiments aimed at manipulating NOTCH1 activation and HES1
expression suggests that the NOTCH1 pathway does not affect the PI3K-PTENAKT/mTOR pathway in HNSCC.
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CHAPTER 1: INTRODUCTION
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1.1 Head and Neck Squamous Cell Carcinoma
Head and neck squamous cell carcinoma (HNSCC) ranks among the most lethal,
common non-skin types of cancer around the world. The disease affects ~600,000
people around the world annually (Jemal et al., 2011). More than five hundred thousand
new cases of HNSCC occurred in 2011 alone, with 50,000 reported cases in the United
States (Agrawal et al., 2011). These trends make HNSCC the seventh most common
non-skin cancer worldwide (Ferlay et al., 2015). HNSCC affects various mucosal sites of
the upper aerodigestive tract, including the nasal cavity, the oral cavity, the larynx, and
the pharynx. Figure 1 illustrates the regions of the upper aerodigestive tract that are
affected by head and neck cancer. Tobacco use, alcohol consumption, and infection with
high-risk types of human papillomavirus (HPV) are major risk factors for developing
HNSCC (Stransky et al., 2011). In fact, the combination of tobacco and heavy alcohol
consumption has a strong synergistic effect on worsening disease prognosis. The 5-year
survival rate is only ~50% in head and neck cancer (Jemal et al., 2011; Kamangar et al.,
2006). Although previous research has made significant epidemiological and
pathological advancements, survival rates have not improved much over the last 40
years (Agrawal et al., 2011). Some treatment methods can result in various cosmetic
deformities and impaired vital functions, such as difficulty breathing, swallowing,
speaking, tasting, hearing, and smelling. Cetuximab, a monoclonal antibody targeting
epidermal growth factor receptor (EGFR), is currently the only approved targeted therapy
for treating head and neck cancer. However, only a subtle improvement has been
detected in the overall survival of head and neck cancer patients (Baselga et al., 2005).
A deeper understanding of this morbid malignancy’s pathogenesis and the role of
recently identified genetic mutations is needed to develop more effective and targeted
therapeutic approaches.
2

Figure 1: Anatomy of Head and Neck Squamous Cell Carcinoma.
Head and neck squamous cell carcinoma affects various mucosal sites of the upper
aerodigestive tract. This encompasses the nasal cavity, the oral cavity, the paranasal
sinuses, the tongue, the salivary glands, the larynx, and the pharynx (including the
nasopharynx, the oropharynx, and the hypopharynx). Permission obtained from Argiris,
A., Karamouzis, M.V., Raben, D., Ferris. R.L. (2008). Lancet. 371, 1695-1709. (Argiris et
al., 2008).
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1.2 PI3K-PTEN-AKT/mTOR pathway
The phosphoinositide-3-kinase (PI3K) pathway is perhaps the most frequently
activated signaling pathway in human cancer. It plays a key role in the regulation of
multiple cellular events, including cell growth, proliferation, cell cycle progression, and
survival (Vivanco and Sawyers, 2002). PI3Ks phosphorylate the 3’-hydroxyl group of
phosphatidylinositides. The PI3K family of enzymes is divided into three main classes
(classes I-III), based on the structure and substrate specificity of each of the enzymes.
Class I PI3Ks are those most often implicated in a wide array of human cancers
(Engelman, 2009). In mammals, class I PI3Ks are further divided into subclasses, IA and
IB, based on their modes of regulation. Class IA PI3Ks are heterodimers that comprise
a regulatory subunit (p85), which mediates binding of the enzymatic ligand to membrane
growth factor receptors, and one of four catalytic subunits (p110α, -β, -γ, or -δ), which
are responsible for the activity of the enzyme (Engelman, 2009). The genes PIK3CA,
PIK3CB, and PIK3CD encode the three highly homologous class IA catalytic isoforms:
p110α, p110β, and p110δ, respectively. These isoforms associate with any of the five
regulatory isoforms: p85α (and its splicing variants, p55α and p50α), p85β, and p55γ,
which are collectively called p85-type regulatory subunits (Engelman et al., 2006). Class
IB PI3Ks are heterodimers of a p110γ catalytic subunit, encoded by PIK3CG, coupled
with the regulatory isoforms, p101 or p87 (Liu et al., 2009). Whereas p110α and p110β
are ubiquitously expressed, p110δ and p110γ expression are generally restricted to
leukocytes (Okkenhaug and Vanhaesebroeck, 2003).
Activated by autocrine signaling, the PI3K/mTOR pathway plays a critical role in
cancer cell activation and provides self-sustaining growth signals to tumors. The pathway
can also be activated by paracrine signaling. In the absence of activating signals, p85
interacts with p110 to inhibit p110 kinase activity. Following receptor tyrosine kinase
4

(RTK) or G protein-coupled receptor (GPCR) activation, class I PI3Ks are recruited to
the plasma membrane, where p85-mediated inhibition of p110 is relieved and p110
phosphorylates

phosphatidylinositides

4,5-biphosphate

(PIP2)

to

generate

phosphatidylinositides 3,4,5-triphosphate (PIP3). The lipid product, PIP3, acts as a
second messenger of the pathway. It can activate AKT-dependent and AKT-independent
downstream signaling pathways (Vanhaesebroeck et al., 2010).
AKT (protein kinase B) is a serine/threonine kinase expressed as three isoforms:
AKT1, AKT2, and AKT3. All three isoforms share a similar structure: an N-terminal PH
domain, a central serine/threonine catalytic domain, and a small C-terminal regulatory
domain (Lu et al., 2012). Activation of AKT is initiated by its translocation to the plasma
membrane, where the PH domain in the N-terminal region of the kinase docks to PIP3.
This results in a conformational change in AKT, exposing two amino acid residues that
are critical to the phosphorylation and activation of AKT. The full activation of AKT
requires the phosphorylation of threonine 308 (Thr308) by PDPK1 (phosphoinositidedependent protein kinase 1) and the phosphorylation of serine 473 (S473) by PDPK2
(phosphoinositide-dependent protein kinase 2) (Velichkova et al., 2010). Under most
circumstances, mTORC2 is the primary source of PDPK2. Once activated, AKT
phosphorylates various other proteins, including GSK3 (glycogen synthase kinase 3) and
FOXOs (the forkhead family of transcription factors). Thus, AKT regulates a wide array
of cellular processes involved in protein synthesis, cell survival, cell proliferation, and
metabolism (Parsons, 2004).
mTOR (mammalian target of rapamycin) belongs to a group of serine/threonine
protein kinases that are referred to as class IV PI3Ks. The kinase serves as a pivotal
regulator of cell growth, cell survival, and cell proliferation by monitoring nutrient
availability, cellular energy and oxygen levels, and mitogenic signals (Song et al., 2012).
5

mTOR also plays a key role in tumorigenesis. mTOR exists in two structurally distinct
complexes: mTORC1 and mTORC2. The mTORC1 complex is composed of the mTOR
catalytic subunit, Raptor (regulatory associated protein of mTOR), PRAS40 (proline-rich
AKT substrate 40 kDa), and the protein mLST8/GbL. mTORC2 is composed of mTOR,
Rictor (rapamycin insensitive companion of mTOR), mSIN1 (mammalian stressactivated protein kinase interacting protein 1), and mLST8/GbL (Chang et al., 1997).
While mTORC1 controls protein synthesis by activating translation of proteins, mTORC2
affects metabolism and cell survival by fully phosphorylating and thus activating AKT.
However, mTORC2 is less defined than mTORC1.
Partial AKT activation is sufficient to activate mTOR. AKT activates mTOR by
directly phosphorylating tuberous sclerosis complex 2 (TSC2) to attenuate its inhibitory
effects on mTOR1 (Klippel et al., 1996). The tuberous sclerosis complex (TSC), an
essential negative regulator of mTORC1 activity, comprises tuberous sclerosis complex
1 (TSC1; hamartin) and tuberous sclerosis complex 2 (TSC2; tuberin). TSC2 functions
as a GTPase-activating protein (GAP) for Rheb. The active, GTP-bound form of Rheb
directly interacts with mTORC1 to stimulate its activity. As a Rheb-specific GAP, TSC2
negatively regulates mTORC1 signaling by converting Rheb into its inactive GDP-bound
state. TSC1 does not have a GAP domain, but it acts as a stabilizer of TSC2 by protecting
it from degradation (Klippel et al., 1996). Hence, the TSC complex functions as a tumor
suppressor.
The best characterized downstream targets of mTORC1 are S6K1 (p70S6 kinase)
and eukaryotic translation initiation factor 4E (eIF4E)-binding protein 1 (4EBP1). Both
effectors are critically involved in regulating protein synthesis and protein translation,
respectively. S6K1 is a serine/threonine kinase that belongs to the family of AGC
kinases. It is responsible for phosphorylating its core substrate, rpS6 (ribosomal protein
6

S6), resulting in cell growth and cell size regulation. While the activating phosphorylation
of rpS6 at serines 240 and 244 (S240/244) are mediated by the PI3K/mTOR pathway,
the activating phosphorylation of rpS6 at serines 235 and 236 (S235/236) are mediated
by MEK/ERK pathway (Meyuhas, 2008). 4EBP1 is a member of a family of translation
repressor proteins. It prevents translation initiation by binding to the translation factor,
eIF4E. The interaction of hypo-phosphorylated 4EBP1 and eIF4E prevents its interaction
with eIF4G, thereby blocking complex assembly and repressing translation. Inhibitory
phosphorylation of 4EBP1 at serine 65 (S65) by mTORC1 causes its release from eIF4E,
allowing cap-dependent translation to proceed (Ma et al., 2009). Thus, the activation of
mTOR provides tumor cells with a growth advantage by promoting protein synthesis.
The primary negative regulator of the PI3K pathway is the phosphatase and tensin
homolog (PTEN). It negatively regulates the PI3K/mTOR pathway by removing the 3phosphate from PIP3, converting it back to PIP2 (Chia et al., 2010). PTEN is a lipid
phosphatase that attenuates the proliferative phenotype of various types of cancer cells
by antagonizing the activity of PI3K. Thus, PTEN serves as an essential tumor
suppressor. Although PTEN is a highly stable protein, it is tightly regulated at the
transcriptional level and is often regulated by post-translational modifications. While
methylation of the promote region inactivates the PTEN gene, phosphorylation of PTEN
at amino acid residues, serine 380 as well as threonines 382 and 383, inhibits protein
activity (Salmena et al., 2008). A simplified illustration of the PI3K-PTEN-mTOR pathway
is depicted in Figure 2.
Genetic alterations in the PI3K pathway have been associated with a great deal
of cancers. Hyperactivity of the PI3K pathway is one of the most prominent
characteristics of many human tumors. Current research reports that pathway activity is
upregulated in 30-50% of prostate cancers (De Velasco and Uemura, 2012; Suzuki et
7

al., 1998). Class IA PI3Ks are mutated and amplified in a wide array of cancer types. The
PIK3CA gene encodes the p110α catalytic subunit of PI3K. It was found to be frequently
mutated in 27% of breast cancers, 23% of endometrial cancers, 14% of colorectal
cancers, 17% of urinary tract cancers, and 8% of ovarian cancers (Samuels et al., 2004).
Most frequently activated mutations (also called “hot- spots”) in PI3K are located within
the kinase domain, H1047, and the helical domains, E542 and E545 (Samuels et al.,
2004). 4-10% of esophageal squamous cell carcinomas exhibit activating mutations of
PIK3CA. Mutations within the E542K and E545K hot-spots and the H1047R substitutions
were the most common (Song et al., 2014). Furthermore, 40% of esophageal tumors
present an increase in PIK3CA copy number, a feature that is associated with poor
disease prognosis (Akagi et al., 2014; Lin et al., 2014; Song et al., 2014).
One common mechanism promoting aberrant PI3K signaling is the somatic
ablation of PTEN by genetic and epigenetic modifications. The PTEN gene maps to the
human chromosome 10q23.3, a region that displays high rates of heterozygosity loss in
various cancer types, including kidney, lung, breast, and prostate cancer (Kwabi-Addo
et al., 2001). Previous research suggests that in aggressive forms of prostate cancer,
the PTEN gene is subject to DNA sequence alterations and point mutations that inhibit
the activity of the PTEN protein (Dong, 2006). Ablation of PTEN often results in
unrestrained signaling of the PI3K pathway, which may lead to tumorigenesis. In fact,
loss of PTEN in most cancer types leads to hyper-activation of AKT, which is associated
with uncontrollable cell proliferation, decreased apoptosis, and enhanced tumor
angiogenesis (Carnero et al., 2008). Taken together, the findings suggest that the loss
of the tumor suppressive function of PTEN is critically linked to tumorigenesis and cancer
progression.

8

Figure 2: The PI3K-PTEN-AKT/mTOR pathway.
Activation of the PI3K/mTOR pathway via endogenous stimuli, exogenous signals, or
mutations promotes cell growth, proliferation, cell cycle progression, and survival. The
PI3Ks are a complex of heterodimers that encompass regulatory and catalytic subunits.
Upstream cellular receptors (such as RTKs and GPCR) promote the activation of the
PI3Ks, which initiates a downstream signaling cascade via phosphorylation. The PI3Ks
phosphorylate the membrane phospholipid substrate, PIP2, converting it into PIP3. PTEN
is a phosphatase that reverts the activity of PI3K by removing the 3-phosphate from PIP3,
converting it back to PIP2. Therefore, an inactivating mutation or loss of PTEN leads to
hyper-activation of the PI3K/mTOR pathway. PIP3 then recruits AKT to the plasma
membrane, where PDK1 and PDK2 fully activate AKT by phosphorylating Thr308 and
S473, respectively. Once activated, AKT phosphorylates and inhibits the TSC1/2,
leading to the activation of the mTOR complex (mTORC1 and mTORC2). Activated
mTORC1 phosphorylates downstream effectors, S6K1 and 4EBP1. Thus, the PI3KPTEN-mTOR pathway can control essential cancer cell processes, including
proliferation, invasion, metastasis, and response to therapy. Permission obtained from
Giudice, F., and Squarize, C. (2013). J Carcinogene Mutagene. S5: 003. (Giudice et al.,
2013).
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1.3 PI3K-PTEN-AKT/mTOR pathway in HNSCC
The PI3K/AKT/mTOR pathway plays a key role in regulating several cellular
processes in normal and cancer cells, including proliferation, growth, invasion, migration,
and survival. Currently, the PI3K/AKT/mTOR is the most frequently altered pathway in
HNSCC. Approximately 80% of HNSCC tumors contain genetic alterations in one or
more components of the pathway (Iglesias-Bartolome et al., 2013; Lui et al., 2013).
According to the most current data produced by the head and neck cohort of The Cancer
Genome Atlas (TCGA), 18% of 510 HNSCC tumors exhibit mutations in the PIK3CA
gene (Gao et al., 2013). The frequency of the pathway alterations promotes poor disease
prognosis.
In HNSCC, particularly, the type and frequency of genetic alterations in the
PI3K/mTOR pathway vary immensely. Many of the alterations occur in the PIK3CA gene.
Findings of recent research report gain-of-function mutations in PIK3CA in 6-20% of
tumors. Other studies report PIK3CA overexpression in 52% of tumors and PIK3CA
amplification in 30% of tumors. The hot-spot substitutions, E542K, E545K, and H1047R,
were the most common (Agrawal et al., 2011; Stransky et al., 2011; Suda et al., 2012;
Lui et al., 2013). Some of the alterations also occur in PTEN, both at the gene and protein
levels. Previous research findings report loss of heterozygosity (LOH) of PTEN in 8% of
tumors and inactivating PTEN mutations in 4% of tumors. Likewise, reduced PTEN
protein expression occurred in 30% of tumors (Squarize et al., 2013; Morris et al., 2011).
There were also mutations in the PIK3CG gene in 4% of tumors (Agrawal et al., 2011;
Stransky et al., 2011). Furthermore, while mutations in the AKT and mTOR genes occur
rarely, phosphorylation of AKT and S6 at the protein level are frequently exhibited in
almost all HNSCC tissues (Lui et al., 2013; Molinolo et al., 2007). This phosphorylation
is an indication of constitutive pathway activation.
10

1.4 PI3K/mTOR pathway inhibition in HNSCC
The frequent activation of the PI3K/mTOR pathway in HNSCC and the pathway’s
significant effect of cancer cell signaling make it a promising target for desperately
needed improvements in various cancer therapies. Because the pathway’s activation is
regulated by identifiable genetic alterations, it is important to use suitable biomarkers for
predicting response to those therapies. For these reasons, many pharmaceutical
companies and academic laboratories are actively developing inhibitors to target the
entire pathway and its key components. Wortmannin and LY294002 are two well-known,
first generation PI3K inhibitors. Wortmannin binds irreversibly binds to PI3K enzymes by
covalently modifying a lysine necessary for catalytic activity, while LY294002 is a smallmolecule inhibitor that reversibly targets the PI3K family members (Liu et al., 2009).
Unfortunately, both inhibitors have miniscule selectivity for the distinct isoforms of PI3K
and are rather toxic in animals (Knight and Shokat, 2007). Despite their limitations, the
preclinical studies influenced by the inhibitors have greatly contributed to our
understanding of the biological significance of the PI3K pathway.
Several compounds targeting PI3K activity have been introduced into clinical
trials, with many of them being dual PI3K/mTOR inhibitors. BEZ235 inhibits multiple class
I PI3K isoforms and mTOR kinase activity by binding to the ATP-binding pocket (Maira
et al., 2008). Preclinical data suggests that it displays strong anti-proliferative properties
on tumor xenografts that exhibit many key genetic alterations in the PI3K pathway,
including PTEN ablation and gain-of-function PI3K mutations (Serra et al., 2008).
BEZ235 has entered Phase I clinical trials in patients with solid tumors (GarciaEcheverria and Sellers, 2008). BGT226 and BKM120, a selective class I PI3K inhibitor
with no inhibitor effects on mTOR activity, have also entered Phase I clinical trials (Knight
and Shokat, 2007).
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Previous studies report that head and neck tumors with activating alterations in
PIK3CA respond better to targeted therapies with specific PI3Kα inhibitors (Elkabets et
al., 2013; Mazumdar et al., 2014). Of note, the first-in-human clinical trial of BYL719, a
specific PI3Kα inhibitor, in solid tumors (NCT01387321) reported that eight patients with
head and neck tumors harboring PI3KCA mutations had a clinical response to therapy
(Baselga et al., 2014, Annals of Oncology, abstract). Despite the frequent activation of
the PI3K/mTOR pathway in HNSCC, using various chemical inhibitors to attenuate
pathway activity has resulted in variable efficacy in vitro and in vivo.

1.5 NOTCH pathway
The NOTCH signal transduction pathway assumes numerous roles in various
developmental processes. NOTCH signaling serves as a critical determinant of cellular
fate within a vast array of tissues. The pathway regulates cell growth, differentiation, and
apoptosis (Artavanis-Tsakonas et al.,1999). Activated by juxtacrine signaling, the
interaction between the receptor of the signal-receiving cell and the ligand of the signalsending cell activates the signaling cascade of the NOTCH pathway. There are four
mammalian NOTCH receptors (NOTCH1-4). The receptors are evolutionarily conserved
single-pass, heterodimeric transmembrane proteins composed of an extracelluar
(NECD) domain, a transmembrane (NTM) domain, and a NOTCH1 intracellular (NICD)
domain. Additionally, there are five ligands: Delta-like (Dll-1, Dll-3, and Dll-4) and Jagged
(Jagged-1 and Jagged-2), all of which are expressed on adjacent cells (Hansson et al.,
2004). Figure 3 depicts the canonical NOTCH pathway.
Upon activation of the pathway, the ligand of the neighboring cell binds to the
receptor of the NOTCH pathway, initiating a signaling cascade within the pathway. In the
signal-receiving cell, NOTCH receptors are processed in the endoplasmic reticulum and
12

the Golgi apparatus via glycosylation and the first proteolytic cleavage, generating a
calcium-stabilized heterodimer. The heterodimer, which consists of the NECD that is
non-covalently attached to the TM-NICD complex, is transported to the plasma
membrane of the cell by endosomes (Weinmaster, 1997). The receptor then undergoes
two subsequent ligand-dependent proteolytic cleavages events. The second proteolytic
cleavage involves tumor necrosis factor-α-converting enzyme (TACE), a transmembrane
protein that includes an extracellular zinc-dependent protease domain. TACE cleaves
the extracellular site of the NOTCH receptor between amino acid residues, alanine 1710
and valine 1711, leaving the NECD bound to the ligand of the signal-sending cell (Mumm
and Kopan, 2000).
The third proteolytic cleavage involves γ-secretase, an integral membrane protein
that cleaves transmembrane proteins at amino acid residues within the transmembrane
domain. The γ-secretase complex consists of presenilin, nicastrin, Pen-2, and Aph-1.
The γ-secretase complex cleaves the intracellular region of the receptor, releasing the
active form of NICD (Bray, 2006). NICD is then released into the cytoplasm, where it is
subsequently translocated into the nucleus to establish NOTCH signaling and begin
transcription. In the absence of NICD from the nucleus, the NOTCH target gene
expression is inactivated by a complex referred to as “CSL.” The complex encompasses
a transcriptional repressor protein called C protein binding factor 1 (CBF1), Suppressor
of hairless [Su(H)], and Lag1. Once NICD is present in the nucleus, it binds to the CSL
complex, converting CBF1 from a transcriptional repressor to a transcriptional activator
and displacing the other co-repressors (Weinmaster, 1997).
The CSL-NICD complex then recruits a co-activator complex that contains
Mastermind (MAML) and p300. Mastermind (MAML) is a 3-member family of
transcriptional activator proteins. p300 is a histone acetyltransferase that epigenetically
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modifies that structure of chromatin to a form that is amenable to active transcription.
Once the complexes bind efficiently in the nucleus, the NOTCH pathway is fully activated
and transcription takes place (Wu et al., 2000). The NOTCH target genes include AKT,
mTOR, and HES/HEY family members. AKT and mTOR are key components of the
PI3K/mTOR pathway.
HES1 (hairy enhancer of split-1) is one of ten members (HES1-7; HEY1, HEY2,
HEYL) of the HES and HEY families. HES and HEY genes encode nuclear proteins that
suppress transcription. Like HEY1 (hairy enhancer-of-split related with YRPW motif
protein 1), HES1 belongs to the basic helix-loop-helix (bHLH) families of transcription
factors (Leimeister et al., 1999). It represses the transcription of genes that require the
function of a bHLH protein for their transcription. The HES1 protein has a certain type of
domain that contains a helix interrupting protein that binds to the N-box promoter region
of the respective gene, rather than the canonical enhancer box (E-box) (Kageyama et
al., 2007). As a member of the bHLH family, HES1 is a transcriptional repressor that
regulates many cellular processes that influence development. It plays a pivotal role in
cell proliferation and differentiation in embryogenesis (Kageyama et al., 2008).
The NOTCH1 pathway is complex because it can assume different roles in
different cancer types. NOTCH1 can act as an oncogene or a tumor suppressor,
depending on the context of the cancer. It is well-documented in the literature NOTCH1
functions as an oncogene in various types of leukemias and lymphomas. NOTCH1 was
first identified as an oncogene in T-cell acute lymphoblastic leukemia, where activating
NOTCH1 mutations in T-cell acute lymphoblastic leukemia (T-ALL) led to ligandindependent NOTCH1 signaling (Weng et al., 2004). NOTCH1 exhibits oncogenic
signaling in approximately 60% of human T-ALL tumors (South et al., 2012). The same
role was later established in other B cell malignancies, such as chronic lymphocytic
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leukemia (CLL) and mantle cell lymphoma (MCL), and breast adenocarcinomas. While
NOTCH1 functions as an oncogene in 5-12% of CLL tumors and approximately 10% of
MCL tumors, it functions as an oncogene in less than 5% of breast adenocarcinomas
(South et al., 2012).
NOTCH1 serves as a tumor suppressor in many different types of squamous cell
carcinomas (SCCs). The tumor suppressor role of NOTCH1 signaling was first reported
by the Radtke group. Their research showed that conditional knock out of NOTCH1
increased tumor incidence in squamous cell skin carcinomas (Radtke and Raj, 2003).
Currently, active NOTCH1 signaling exerts tumor suppressive properties on 60-70% of
squamous cell skin carcinomas. Additionally, NOTCH1 functions as a tumor suppressor
in 5-10% of lung squamous cell carcinoma tumors (South et al., 2012). The diverse
function of NOTCH1 in the context of a cancer cell renders it a novel targeting agent for
improving modern cancer therapies.
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Figure 3: The NOTCH pathway.
The NOTCH pathway plays a key role in regulating cell fate determination, cell
differentiation, and apoptosis. Upon activation, the intracellular domain of the NOTCH1
receptor (NICD) is cleaved. NICD then enters the cytoplasm and is translocated to the
nucleus, where it aids in the transcription of various target genes. Permission obtained
from Amsen, D., Antov, A., Flavell, R. A. (2009). Nature Reviews Immunology. 9, 116124. (Amsen et al., 2009).
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1.6 NOTCH1 pathway in HNSCC
Understanding the NOTCH1 pathway is essential to developing targeted
therapies for head and neck squamous cell carcinoma. Multiple groups have performed
whole exome sequencing on head and neck tumors and discovered frequent NOTCH1
mutations in HNSCC (Agrawal et al., 2011; Stransky et al., 2011; Pickering et al., 2013).
These findings were confirmed by the most current data produced by the head and neck
cohort of The Cancer Genome Atlas (TCGA), in which NOTCH1 mutations have a
prevalence of approximately 18% in 510 HNSCC patient tumor samples (Gao et al.,
2013). Of note, the majority of mutations are predicted to be inactivating NOTCH1
mutations. Findings of recent research identified a pattern of truncating NOTCH1
mutations that occurred frequently in HNSCC. Particularly, 28 NOTCH1 mutations in 21
patients with HNSCC tumors predicted tumor suppressive properties (Agrawal et al.,
2011).
More specifically, the oncogenic NOTCH1 mutations exhibited by T-ALL occur in
two locations along the gene. The first hot-spot consists of generally missense mutations
within the negative regulatory heterodimerization domain. The second hot-spot consists
of frequent truncating mutations near the C-terminus, leading to a deletion in the PEST
domain and causing a markedly increased stabilization of constitutively activated
NOTCH1 in the nucleus (Ferrando, 2009). In HNSCC, however, the distribution of
inactivating NOTCH1 mutations is completely different from the activating NOTCH1
mutations found in T-ALL. There are some truncating mutations dispersed throughout
the gene, but they are not located in the PEST domain. Most of the missense mutations
cluster in the extracellular EGF-like binding domain, thereby preventing the NOTCH1
receptor from binding to the ligand and blocking NOTCH1 signaling (Pickering et al.,
2014). The findings suggest that the NOTCH1 mutations in HNSCC are loss-of-function
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mutations. Figure 4 is an illustration of the locations of the mutations in T-ALL and
HNSCC along the NOTCH1 gene.
The results of the next generation sequencing analysis on HNSCC tumors and
the mutational landscaping of NOTCH1 in both cancer types support the hypothesis that
NOTCH1 functions as a tumor suppressor in head and neck squamous cell carcinoma,
unlike its well-established role as an oncogene in T-ALL. Researchers subsequently
demonstrated that restoring NOTCH1 receptors with active NOTCH1 signaling to
NOTCH1 mutant HNSCC cell lines inhibited their in vitro growth on external ligands as
well as their in vivo growth in mice (Pickering et al., 2013). Currently, inactivating
NOTCH1 mutations have been discovered in a vast number of solid tumors derived from
skin, lung, and esophageal squamous cell carcinomas (Pickering et al., 2014; group Tw,
2012; Agrawal et al., 2012). Taken together, the findings support the observation that
NOTCH1 is one of the most frequently occurring and commonly mutated novel genes in
HNSCC (Agrawal et al., 2011).
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Figure 4: Genetic locations of NOTCH1 mutations in T-ALL and HNSCC.
There are different patterns of NOTCH1 mutations in T-ALL and HNSCC. Missense,
truncating, and in-frame indel mutations are indicated with green, black, and brown dots,
respectively. The NOTCH1 domains are color-coded, with the heterodimerization (HD)
and Lin-NOTCH repeat (LNR) domains constituting negative regulatory regions
(Pickering et al., 2014; Figure: Mitchell J. Frederick, PhD).
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1.7 Sensitivity of NOTCH1 mutants to PI3K/mTOR inhibitors
To identify novel, translationally applicable molecular vulnerabilities to
PI3K/mTOR pathway inhibitors, our laboratory used a pharmacogenomics approach to
integrate drug sensitivity data for seven diverse PI3K/mTOR pathway inhibitors with
multiple ‘omic’ data on a panel of molecularly characterized HNSCC cell lines. The
association between drug response and molecular characteristics in the respective cell
lines was studied. Sixty-eight head and neck squamous cell carcinoma cell lines were
analyzed. They were stratified into 3 groups, based on their genotype. The cell lines were
treated with 2 dual PI3K/mTOR inhibitors, exclusively, and cell viability was measured.
Based on the best dose-response model, IC 70 values were generated for each cell line.
The same cell lines were also treated with selective class I PI3K and pan-PI3K
inhibitors. The drug screening experiments in the laboratory revealed that the cell lines
that harbored NOTCH1 and PIK3CA mutations were more sensitive to the selective class
I PI3K, the pan-PI3K, and the dual PI3K/mTOR inhibitors than their wild-type
counterparts. Drug-induced apoptosis was also measured. The cell lines treated with
dual PI3K/mTOR inhibitors exhibited significant increases in cell death. The results,
however, were irrespective of the PIK3CA status of the cell lines. NOTCH1 mutant
HNSCC cells lines were sensitive to dual PI3K/mTOR inhibitors and underwent
apoptosis. An independent study reported that NOTCH1 mutant tumors found in two
HNSCC patient derived xenografts (PDXs) were sensitive to a PI3K inhibitor in vivo
(Keysar et al., 2013). The preclinical data produced by our lab suggests that HNSCC
patients with NOTCH1 mutations may have an even better response to PI3K/mTOR
inhibitors than those patients that harbor PIK3CA mutations.
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1.8 Potential NOTCH1 and PI3K-PTEN-AKT/mTOR interactions
The interaction between the NOTCH1 and PI3K-PTEN-AKT/mTOR pathways
is well known in T-ALL. Constitutively active NOTCH1 signaling contributes to more than
half of all cases of T-ALL (Weng et al., 2004). Initially, using γ-secretase inhibitors (GSIs)
to block the proteolytic cleavage of NOTCH1 proved effective in inducing cellular growth
arrest and apoptosis in some T-ALL cell lines. However, the GSI treatment failed to
prevent the growth of NOTCH1 mutant T-ALL cell lines. The findings suggest a
mechanism of resistance that NOTCH1 mutant T-ALL cell lines employ to overcome
various therapies. Subsequent research demonstrates that in T-ALL cell lines, a key
indicator of resistance to GSI-mediated NOTCH1 inhibition is homozygous loss of PTEN.
Studies further show that PTEN expression is negatively regulated by HES1, a pivotal
downstream target of the NOTCH1 pathway (Palomero et al., 2007). Additionally,
γ-secretase-mediated NOTCH1 inhibition was shown to be synergistic with the inhibition
of mTOR, a downstream effector of PI3K/AKT signaling, in T-ALL cell lines. The results
were irrespective of the cell lines’ sensitivity to the GSI treatment (Chan et al., 2007).
In some T-ALL cases, for instance, active NOTCH1 signaling leads to the
transcriptional repression of PTEN and subsequent activation of the PI3K/AKT/mTOR
pathway, which leads to cell survival and proliferation. In other T-ALL cases, NOTCH1
inhibition leads to upregulated PTEN that inhibits the PI3K/AKT/mTOR pathway and
results in cell growth arrest and apoptosis. Additionally, T-ALL tumor cells survive and
proliferate when both pathways are activated and no PTEN is present. Furthermore,
T-ALL tumors that lack PTEN and active NOTCH1 signaling retains active
PI3K/AKT/mTOR pathway signaling that promotes cellular survival and proliferation
(Gutierrez and Look, 2007). The findings support a common indication: PTEN must be
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present in the cell to inhibit the PI3K/AKT/mTOR pathway and prevent cell proliferation
and survival.
Presumably, T-ALL tumors that possess mutations or deletions in PTEN are
capable of constitutively inhibiting PTEN via the NOTCH1-HES1 pathway. The genetic
alteration renders the cells resistant to GSIs by preventing the reactivation of PTEN,
which typically occurs when NOTCH signaling is blocked. The findings also suggest that
PTEN serves as a prominent mediator of communication between the NOTCH1 and
PI3K/AKT/mTOR pathways in T-ALL. The interaction between both pathways is largely
unknown in HNSCC. Because NOTCH1 has a different role in T-ALL than it does in
HNSCC, the interactions may also be distinct. Elucidating the mechanism of
communication between the NOTCH1 and PI3K/AKT/mTOR pathways in HNSCC may
aid in the development of target therapies for patients with HNSCC tumors. After all,
there are no effective targeted therapies for cancers driven by the loss of tumor
suppressive properties.
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1.9 Central Hypothesis and Specific Aims
The central goal of the project was to elucidate the mechanism of communication
between the NOTCH1 and PI3K-PTEN-AKT/mTOR pathways in HNSCC.

More

specifically, we investigated whether the NOTCH1 pathway regulates the activity of the
PI3K-PTEN-AKT/mTOR pathway in HNSCC in vitro. Figure 5 is a diagram of the potential
interaction between the NOTCH1 pathway and the PI3K-PTEN-AKT/mTOR pathway in
HNSCC in vitro. We hypothesized that NOTCH1-mediated upregulation of HES1
promotes downregulation of PTEN transcription and activation of the PI3K/AKT/mTOR
pathway in HNSCC.
Specific Aim 1: To determine if HES1 is regulated by NOTCH1 signaling in
HNSCC cell lines.
A.

To determine if basal levels of HES/HEY family members are different in

NOTCH1 mutant and wild-type HNSCC cell lines
We collaborated with the Department of Bioinformatics and Computational Biology who
applied modified two-sample t-tests analyses to cleaved NOTCH1 (NICD) reverse phase
protein array (RPPA) values and HES/HEY RNA sequence (RNA-seq) values to identify
differentially expressed variables between the comparative groups. They also applied
Spearman correlation and Pearson correlation analyses to the data sets to identify
correlated variables between the comparative groups. We hypothesized that there would
be a direct positive correlation between mRNA expression of each of the HES and HEY
family members and cleaved NOTCH1 status.
B.

To determine if levels of HES1 change when we inhibit NOTCH1 signaling

in NOTCH1 wild-type HNSCC cell lines
We employed three methods of manipulation to inhibit NOTCH1 signaling in NOTCH1
wild-type HNSCC cell lines. We (1) blocked NOTCH1 signaling using OMP-52M51, a
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NOTCH1 monoclonal blocking antibody; (2) silenced NOTCH1 gene expression using
siRNA targeting the NOTCH1 receptor gene; and (3) obtained NOTCH1-/- cell lines from
Dr. Mitchell Frederick’s laboratory. We measured NOTCH1 pathway, HES1, and PI3KPTEN-AKT/mTOR pathway protein levels via western blot. We also measured NOTCH1,
HES1, and PTEN mRNA levels via qRT-PCR. We hypothesized that inhibiting NOTCH1
signaling would downregulate HES1 gene and protein expression, leading to upregulated
PTEN transcription and protein activity, and the subsequent inactivation of the
PI3K/AKT/mTOR pathway.
C. To determine if levels of HES1 change when we induce NOTCH1 signaling in
NOTCH1 mutant HNSCC cell lines
We administered doxycycline to induce the NOTCH1 intracellular domain (NICD)
expression system in NOTCH1 mutant HNSCC cell lines. We measured NOTCH1
pathway, HES1, and PI3K-PTEN-AKT/mTOR pathway protein levels via western blot.
We also measured NOTCH1, HES1, and PTEN mRNA levels via qRT-PCR. We
hypothesized that restoring active NOTCH1 signaling would upregulate HES1 gene and
protein expression, leading to downregulated PTEN transcription and protein activity,
and the subsequent hyper-activation of the PI3K/AKT/mTOR pathway.
Specific Aim 2: To determine if HES1 regulates the PI3K-PTEN-/AKT/mTOR
pathway.
A.

To determine if PI3K-PTEN-AKT/mTOR pathway target protein levels

change when we silence HES1 gene expression in NOTCH1 wild-type HNSCC cell lines
We silenced HES1 gene expression in NOTCH1 wild-type HNSCC cell lines using siRNA
targeting the HES1 gene. We measured NOTCH1 pathway, HES1, and PI3K-PTENAKT/mTOR pathway protein levels via western blot. We also measured NOTCH1, HES1,
and PTEN mRNA levels via qRT-PCR. We hypothesized that silencing the HES1 gene
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would downregulate HES1 protein expression, upregulate PTEN transcription and
protein activity, and lead to the subsequent inactivation of the PI3K/AKT/mTOR pathway.
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Figure 5: Potential NOTCH1 and PI3K-PTEN-AKT/mTOR pathways interaction.
Active NOTCH1 signaling will lead to the active transcription of HES1 and subsequently
upregulate HES1 gene expression. In turn, HES1 will transcriptionally repress PTEN
transcription and subsequently downregulate PTEN gene expression. The ablated
activity of PTEN will lead to the hyper-activation of the PI3K/AKT/mTOR pathway.
(Figure: Vaishnavi Sambandam, PhD).
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2.1 HNSCC Cell Lines
A panel of 68 HNSCC cell lines were obtained from sources delineated in (Zhao
et al., 2011) and maintained as directed. The cell lines were profiled for authenticity by
Short Tandem Repeat (STR) analysis. They were tested for mycoplasma contamination
using a Mycoplasma detection kit (Lonza). All cell lines were mycoplasma free at the
time of testing. The assembly, characterization, and STR profiles for all of the cell lines
are also described in (Zhao et al., 2011). The CRISPR/Cas9 knock out cell lines and the
doxycycline inducible Notch1 intracellular domain (NICD) expression system were
developed by Dr. Mitchell Frederick’s laboratory.

2.2 Cell Culture
All cells were cultured in 1X Dulbecco's Modified Eagle's Medium (DMEM)
complete media containing 10% FBS, 2% Penicillin/Streptomycin, L-glutamine, glucose,
and sodium pyruvate (Corning). Cells were incubated in a 37°C, 5% carbon dioxide
incubator.

2.3 Western blotting
HNSCC cell lines were lysed with 1X Cell Lysis Buffer (20 mM Tris-HCl (pH 7.5),
150 mM NaCl, 1 mM Na2EDTA, 1 mM EGTA, 1% Triton, 2.5 mM sodium pyrophosphate,
1 mM β-glycerophosphate, 1 mM Na3VO4, 1 μg/ml leupeptin; Cell Signaling Technology).
After lysing, cells were incubated on ice and allowed to solubilize in the buffer for 15
minutes. The lysates were then centrifuged at 14,000 x g at 4°C for 15 minutes. The
supernatant was collected and protein concentration was measured using the Pierce
BCA protein assay kit (ThermoFisher Scientific). The lysates were then mixed with 10%
β-mercaptoethanol and 4X Laemmli protein sample buffer (Bio-Rad) and loaded onto 428

20% gradient gels (Mini-PROTEAN TGX Precast Gels; Bio-Rad), based on the
molecular weights of the probed proteins. Gels were run using 10X premixed gel
electrophoresis buffer (25mM Tris, 192 mM glycine and 0.1%SDS at pH 8.3, after mixing
with distilled water; Bio-Rad) at 115 V for 1.5-2 hours. Gels were then turbo-transferred
on nitrocellulose membranes using the Trans-Blot Turbo 5X Transfer Buffer (Bio-Rad)
for 30 minutes in the Trans-Blot Turbo Transfer System (Bio-Rad). After transfer, the
membranes were blocked using 5% milk in TBST for 2 hours with constant rotating
agitation. The membranes were then incubated with the respective primary antibodies at
various concentrations, ranging from 1:1000-1:10000, depending on the binding affinities
of the antibodies. The membranes were then incubated overnight at 4°C with constant
rotating agitation. After incubation, the membranes were washed for 15 minutes with
washing buffer, TSBT containing 0.1% Tween-20, approximately 3 times. Membranes
were then incubated with the respective species-specific horseradish peroxidaseconjugated secondary antibodies for 1 hour at room temperature with constant rotating
agitation. Protein signals were developed using the Pierce ECL Western Blotting
Substrate or the SuperSignal West Pico Chemiluminescent Substrate (ThermoFisher
Scientific), depending on the strength of the protein signals, on an X-ray film. Relative
protein abundance was quantified using ImageJ (Schneider et al., 2012) and the
expression of each protein was normalized against the internal control protein, β-actin,
using the formula, [(target protein value)/(actin value)]. The fold change of protein
expression was calculated using the formula, [(B)/(A)], in which “B” represents the treated
condition of each protein normalized against β-actin and “A” represents the control
condition of each protein normalized against β-actin.
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2.4 Quantitative reverse transcription PCR (qRT-PCR)
Total RNA was extracted using the RNeasy Plus Mini Kit (Qiagen). Cells were
briefly scrapped from the petri dish using a scraper after adding the Buffer RLT Plus
RNeasy Plus lysis buffer solution (Qiagen). The sample lysates were homogenized for 3
minutes using a QIAshredder (Qiagen). The lysates were then mixed with ethanol and
applied to a silica-based filter, which selectively binds mRNA and larger rRNA. The filter
was washed with Buffer RW1 and Buffer RPE wash buffers (Qiagen) to remove residual
DNA and other contaminants. The RNA is then eluted from the filter with nuclease-free
water. RNA concentration was measured using the NanoDrop 2000c spectrophotometer
(Thermo Scientific). cDNA was then synthesized by reverse transcription using the iScript
cDNA Synthesis Kit (Bio-Rad) in a MJ Mini personal thermal cycler (Bio-Rad) as directed
by the manufacturer. A total of 100ng of cDNA was used per reaction, and each reaction
was measured in triplets using a C1000 Touch Thermal Cycler (Bio-Rad). The
expression of each target gene was normalized against the internal control gene,
GAPDH, calculated using the formula, [2^(GAPDH value)-(target protein value)]. The fold
change of gene expression was calculated using the formula, [(B)/(A)], in which “B”
represents the treated condition of each gene normalized against GAPDH and “A”
represents the control condition of each gene normalized against GAPDH.

2.5 Transfection
siRNA transfections were performed using HNSCC cells. Cells were plated at a
density of 2.0x106 the day before transfection. On the day of the transfection,
Lipofectamine RNAiMAX transfection reagent (Invitrogen, Life Technologies) was diluted
in 1X OPTI-MEM Reduced Serum Media (Gibco, Life Technologies). In a separate
Eppendorf tube, the respective siRNA was diluted in 1X OPTI-MEM Reduced Serum
30

Media. The diluted siRNA solution was then added to the diluted Lipofectamine
RNAiMAX reagent solution (1:1 ratio) and incubated at room temperature for 5 minutes.
The siRNA-lipid complex was then added to the cells, which were incubated in a 37°C,
5% carbon dioxide incubator for 24 hours. Protein lysates were then collected at the 24hour time point and analyzed via western blot and qRT-PCR.

2.6 Chemical inhibition
Brontictuzumab (OMP-52M51), a humanized IgG monoclonal antibody against
NOTCH1, was obtained from OncoMed Pharmaceuticals, Inc. Normal mouse IgG, an
isotype control immunoglobulin, was obtained from Santa Cruz Biotechnology, Inc (# sc2025). Drug treatments via chemical inhibition were performed using HNSCC cells. Cells
were plated at a density of 2.0x106 the day before drug administration. On the day of the
treatment, OMP-52M51 and normal mouse IgG were added to the experimental and
control cells, respectively, at a concentration of 0.5ug/ml. The cells were then incubated
in a 37°C, 5% carbon dioxide incubator for 30 minutes, 2 hours, 4 hours, 8 hours, and
24 hours. Protein lysates were then collected at each of the time points and analyzed via
western blot and qRT-PCR.

2.7 siRNAs for NOTCH1 and HES1
The non-targeting control and NOTCH1 siRNAs were obtained from Dharmacon
(GE Life Sciences). Each pool contained four sequences for each gene. The antisense
sequences for the ON-TARGETplus Non-targeting Pool are:
1) UGGUUUACAUGUCGACUAA
2) UGGUUUACAUGUUGUGUGA
3) UGGUUUACAUGUUUUCUGA
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4) UGGUUUACAUGUUUUCCUA
The antisense sequences for the NOTCH1 ON-TARGETplus SMARTpool are:
1) GCGACAAGGUGUUGACGUU
2) GAUGCGAGAUCGACGUCAA
3) GGACAUCACGGAUCAUAUG
4) GAACGGGGCUAACAAAGAU
The HES1 siRNA was obtained from Santa Cruz Biotechnology, Inc (# sc-270146). The
construct consists of a pool of three target-specific, 19-25 nucleotide sequences
designed to silence gene expression.

2.8 Antibodies
The antibodies utilized in this project are outlined in Table 1.

Antibody
NOTCH1-NTM

Cell Signaling

Catalog
Conc.
No.
3439
1:1000

NOTCH2-NTM

Cell Signaling

5732

1:1000

5% BSA + 0.03% NaN3 – TBST

NOTCH3-NTM

Cell Signaling

5276

1:1000

5% BSA + 0.03% NaN3 – TBST

NOTCH4-NTM

Cell Signaling

2423

1:1000

5% BSA + 0.03% NaN3 – TBST

Cleaved
NOTCH1
HES1

Cell Signaling

4147

1:1000

5% BSA + 0.03% NaN3 – TBST

Cell Signaling

11988

1:1000

5% BSA + 0.03% NaN3 – TBST

Cell Signaling

9549

1:1000

5% BSA + 0.03% NaN3 – TBST

Cell Signaling

9552

1:1000

5% BSA + 0.03% NaN3 – TBST

Cell Signaling

4060

1:1000

5% BSA + 0.03% NaN3 – TBST

Cell Signaling

4691

1:1000

5% BSA + 0.03% NaN3 – TBST

Phospho-PTEN
(Ser380/
Thr382/383)
PTEN
Phospho-AKT
(Ser473)
Total AKT

Source
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Diluent
5% BSA + 0.03% NaN3 – TBST

Phospho-S6
(Ser235/236)
Phospho-S6
(Ser240/244)
Total S6

Cell Signaling

2211

1:1000

5% BSA + 0.03% NaN3 – TBST

Cell Signaling

2215

1:1000

5% BSA + 0.03% NaN3 – TBST

Cell Signaling

2217

1:1000

5% BSA + 0.03% NaN3 – TBST

Phospho-4EBP1
(Ser65)
Total 4EBP1

Cell Signaling

13443

1:1000

5% BSA + 0.03% NaN3 – TBST

Cell Signaling

9452

1:1000

5% BSA + 0.03% NaN3 – TBST

β-actin

Cell Signaling

3700

1:10000

5% BSA + 0.03% NaN3 – TBST

Table 1: Description of the antibodies used in the project.

2.9 Primers
The primers utilized in this project are outlined in Table 2.

Gene

Target Sequence(5’-3’)

Source

Forward: CCCATCACCATCTTCCAG
GAPDH

Sigma-Aldrich
Reverse: ATGACCTTGCCCACAGCC

Forward: TCCACCAGTTTGAATGGTCA
NOTCH1

Sigma-Aldrich
Reverse: AGCTCATCATCTGGGACAGG

Forward: CCCAACGCAGTGTCACCTTC
HES1

Sigma-Aldrich
Reverse: TACAAAGGCGCAATCCAATATG

Forward: CCAGGACCAGAGGAAACCT
PTEN

Sigma-Aldrich
Reverse: GCTAGCCTCTGGATTTGA

Table 2: Description of the primers used in the project.
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CHAPTER 3: RESULTS AND ANALYSES
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3.1 HES5 mRNA expression is lower in NOTCH1 mutant than NOTCH1 wild-type
HNSCC cell lines
Previous research suggests that HES1 transcriptionally represses PTEN, leading
to the hyperactivity of the PI3K/AKT/mTOR pathway and increased cell growth, survival,
and proliferation (Gutierrez and Look, 2007; Palomero et al., 2007). Because HES1 is a
member of a family of transcriptional repressors (HES1-7; HEY1, HEY2, HEYL) that can
be regulated by NOTCH, we investigated whether there was a significant correlation
between cleaved NOTCH1 (NICD) status and the mRNA expression of the HES and
HEY family members in HNSCC cell lines. All data was processed and analyzed by
Dr. Jing Wang’s team in the Department of Bioinformatics at M.D. Anderson Cancer
Center. Statisticians applied modified two-samples t-tests to the data sets to identify
differentially expressed variables between the comparative groups. They also applied
Spearman correlation and Pearson correlation analyses to the data sets to identify
correlated variables between the comparative groups.
We hypothesized that there would be a direct positive correlation between the
mRNA expression of each of the HES and HEY family members and the cleaved
NOTCH1 protein levels in the HNSCC cell lines. The scatterplot and barplot in Figure 6
shows that HES5 is the only member of the HES and HEY family of transcriptional
repressors to exhibit increased mRNA levels in HNSCC cell lines possessing high
cleaved NOTCH1 protein [spearman.pval: 0.007; adj.p.val: 0.067]. The scatterplots in
Figure 7 further confirm the findings.
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A

B

Figure 6: HES5 mRNA expression significantly correlated with cleaved NOTCH1
(NICD) protein levels in HNSCC.
[A] Scatterplot comparing NOTCH1 activation status and HES/HEY mRNA expression.
[B] Barplot comparing NOTCH1 activation status and HES/HEY mRNA expression.
Measures of significance are color-coded, with coral bars constituting significant values
and teal bars indicating insignificant values.
(Analysis: Li Shen, PhD & Jing Wang, PhD, Department of Bioinformatics and
Computational Biology)
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A

B

Figure 7: No significant correlation between HES/HEY mRNA expression and
NOTCH1 activation status in HNSCC.
[A] Scatterplots comparing HES family mRNA expression, with the exception of HES5,
and cleaved NOTCH1 (NICD) protein levels in HNSCC cell lines. [B] Scatterplots
comparing HEY family mRNA expression and cleaved NOTCH1 (NICD) protein levels in
HNSCC cell lines. NOTCH1 mutant and NOTCH1 wild-type HNSCC cell lines are
indicated with coral and teal dots, respectively. (Analysis: Li Shen, PhD & Jing Wang,
PhD, Department of Bioinformatics and Computational Biology)
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3.2 NOTCH1 wild-type HNSCC cell lines have diverse levels of NOTCH1 activation
HES1 is a well-established transcriptional target gene of the NOTCH1 pathway.
In other words, active NOTCH1 signaling promotes the active transcription of HES1,
leading to upregulated HES1 mRNA levels. Thus, HES1 mRNA levels were expected to
be positively correlated with cleaved NOTCH1 protein levels in HNSCC cell lines.
Because the results of the Spearman and Pearson correlation analyses were rather
different from our hypothesis, we decided to examine the NOTCH1 activation of the
NOTCH1 wild-type HNSCC cell lines. We collected lysate from 3 NOTCH1 wild-type
HNSCC cell lines (FADU, PJ34, OSC19) after 24 hours and measured the basal protein
levels of NOTCH1, NICD, HES1, and PTEN via western blot analysis.
We expected that NOTCH1 wild-type HNSCC cell lines would display higher
levels of NOTCH1 and NICD basal protein, suggesting increased NOTCH1 activation
due to active NOTCH1 signaling, compared to mutant cell lines. Figure 8 reveals that the
levels of cleaved NOTCH1 (NICD) protein vary across the NOTCH1 wild-type HNSCC
cell lines (with overlapping levels observed in mutants), indicating that the NOTCH1 wildtype HNSCC cell lines have diverse NOTCH1 activation. The diverse NOTCH1 and NICD
protein levels also yielded diverse HES1 and PTEN protein levels across the cell lines.
For instance, while higher protein levels of NOTCH1 and NICD correlated with higher
protein levels of HES1 in some cell lines, lower protein levels of NOTCH1 and NICD
correlated with lower protein levels of HES1 in other cell lines. These results may explain
why the mRNA levels of HES1 did not correlate significantly with the protein levels of
cleaved NOTCH1.
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Notch1
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NICD

Hes1

PTEN

β-actin

Figure 8: Diverse NOTCH1 activation in NOTCH1 wild-type HNSCC cell lines.
[A] Western blot analysis of NOTCH1, NICD, HES1, and PTEN basal protein levels after
24 hours in NOTCH1 wild-type HNSCC cell lines. [B] Bar graph comparing quantification
of protein levels measured via western blot. NOTCH1 wild-type HNSCC cell lines are
color-coded. FADU, PJ34, and OSC19 are indicated in red, purple, and blue,
respectively.
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3.3 Inhibition of NOTCH1 signaling does not significantly affect the PI3K-PTENAKT/mTOR pathway in HNSCC
Preliminary experiments in our laboratory show that NOTCH1 mutant HNSCC cell
lines are sensitive to dual PI3K/mTOR inhibitors. To investigate the mechanism of
sensitivity in the cell lines, we explored the interaction between the NOTCH1 pathway
and the PI3K-PTEN-AKT/mTOR pathway. We treated 3 NOTCH1 wild-type HNSCC cell
lines (FADU, PJ34, and OSC19) at various time points (30 minutes, 2 hours, 4 hours, 8
hours, and 24 hours) with OMP-52M51 at a concentration of 0.5ug/ml. We treated the
control groups of the same cell lines with normal mouse IgG, an isotype control
immunoglobulin, using the same concentration at the same time points. We then
collected lysate and measured NOTCH1 pathway and PI3K-PTEN-AKT/mTOR pathway
protein levels via western blot analysis. Experiments were repeated twice in each cell
line for validity and reliability measures (n=2).
OMP-52M51, also known as Brontictuzumab, is a first-in-class humanized IgG
monoclonal antibody against NOTCH1. The antibody exerts its function by binding to the
negative regulatory region (NRR) of the extracellular domain on the NOTCH1 receptor
and changing its conformation. The conformational change prevents the receptor from
binding to an adjacent ligand and ultimately blocks NOTCH1 signaling (Patnaik et al.,
2014). Figure 9 is a schematic of the functional activity of OMP-52M51 in vitro and in
vivo. Although gamma secretase inhibitors are commonly used to inhibit NOTCH1
signaling, we wanted to use a more specific inhibitor to prevent NICD cleavage. Using
the active signaling of NOTCH1 in T-ALL as a model, we postulated that inhibiting
NOTCH1 signaling in NOTCH1 wild-type HNSCC cell lines would lead to downregulated
HES1 transcription and upregulated PTEN activity,

thereby inactivating the

PI3K/AKT/mTOR pathway. However, results of the experiment yielded a different
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outcome. Figure 10 shows that inhibiting the NOTCH1 pathway has no significant effect
on HES1, PTEN, or the PI3K/AKT/mTOR pathway. While NOTCH1 signaling was
blocked effectively in each cell line, there were no significant or consistent differences
among the respective protein levels of the control and treated samples across the various
time points.
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Figure 9: Activity of OMP-52M51 in vitro and in vivo.
Brontictuzumab, also known as OMP-52M51, is a first-in-class humanized IgG
monoclonal antibody against NOTCH1. It binds to the negative regulatory region (NRR)
of the NOTCH1 extracellular domain on the receptor and changes its conformation,
preventing the receptor from binding to an adjacent ligand and blocking NOTCH1
signaling. Permission obtained from Patnaik, A., LoRusso, P., Munster, P., Tolcher,
A.W., Davis, S.L., Heymach, J., Ferrarotto, R., Xu, L., Kapoun, A.M., Faoro, L., Lewicki,
J.A., Dupont, J., Eckhardt, S.G. (2014). EORTC-NCI-AACR Symposium. (Patnaik et al.,
2014).
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Figure 10: Blocking NOTCH1 signaling has no significant effect on the PI3K-PTENAKT/mTOR pathway.
Western blot analysis and quantification of NOTCH1 pathway and PI3K-PTENAKT/mTOR pathway protein levels after 0.5ug/ml OMP-52M51 treatment for 30 minutes,
2 hours, 4 hours, 8 hours, and 24 hours in [A] FADU, [B] PJ34, and [C] OSC19. Pathway
proteins are color-coded in line graphs.
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3.4 Inhibition of NOTCH1 signaling has differential effects on HES1 and PTEN
transcription in HNSCC
Previous studies show that inhibiting NOTCH1 signaling in NOTCH1 wild-type
HNSCC cell lines has no significant or consistent effect on the PI3K-PTEN-AKT/mTOR
pathway at the protein level. We investigated whether the same trend persisted at the
mRNA level. Because results of the western blot analysis revealed that HES1 protein
levels decreased the most after 8 hours of successful OMP-52M51 treatment, we
repeated the treatment of FADU, PJ34, and OSC19 with 0.5ug/ml of OMP-52M51 for 8
hours and isolated RNA. We then measured NOTCH1, HES1, and PTEN mRNA levels
via qRT-PCR. Experiments were repeated twice in each cell line for validity and reliability
measures (n=2).
We hypothesized that inhibiting NOTCH1 signaling would downregulate HES1
transcription, leading to decreased HES1 mRNA levels and increased PTEN mRNA
levels. Nevertheless, we discovered that the results varied among the cell lines (Figure
11). While HES1 mRNA levels decreased in FADU and PJ34 after blocking NOTCH1
signaling, there was no significant effect on HES1 mRNA levels in OSC19 after
treatment. Of note, there is a subtle decrease in HES1 protein in FADU and PJ34, as
seen in Figure 10, at the same timepoint in which we observe decreased HES1 mRNA
expression in the same cell lines. Moreover, blocking NOTCH1 signaling had no
significant effect on PTEN transcription in FADU, PJ34, or OSC19. Taken together, the
findings of the western blot and qRT-PCR analyses suggest that the well-established
association between NOTCH1, HES1, and PTEN in T-ALL may be weak or nonexistent
in HNSCC.
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Figure 11: Blocking NOTCH1 signaling has differential effects on HES1 and PTEN
transcription in HNSCC.
Quantification of NOTCH1, HES1, and PTEN mRNA levels after qRT-PCR analysis of
FADU, PJ34, and OSC19. Cell lines were treated with OMP-52M51 at a concentration
of 0.5ug/ml for 8 hours. Control and treated samples are denoted in blue and red,
respectively.

48

3.5 Knock down (KD) of NOTCH1 has no significant effect on the PI3K-PTENAKT/mTOR pathway in HNSCC
To test our hypothesis using an independent method, we decided to employ a
more genetic means of inhibiting NOTCH1 signaling. We treated the 3 NOTCH1 wildtype HNSCC cell lines (FADU, PJ34, and OSC19) with 20nM siRNA targeting the
NOTCH1 gene for 24 hours. NOTCH1 protein and mRNA have a half-life of
approximately 1.5 hours, making 24 hours a suitable time point for silencing the NOTCH1
gene (Nedjic and Aifantis, 2010). The control groups of the respective cell lines were
treated with 20nM non-targeting siRNA for 24 hours. We then collected lysate and
measured NOTCH1 pathway and PI3K-PTEN-AKT/mTOR pathway protein levels via
western blot analysis. Experiments were repeated twice in each cell line for validity and
reliability measures (n=2).
We hypothesized that using siRNA to inhibit NOTCH1 signaling would lead to
downregulated HES1 transcription and upregulated PTEN activity, thereby inactivating
the PI3K/AKT/mTOR pathway in NOTCH1 wild-type HNSCC cell lines. However,
Figure 12 shows that genetically blocking NOTCH1 signaling via siRNA has no significant
effect on HES1, PTEN, or the PI3K/AKT/mTOR pathway. Although we successfully
sustained approximately 70% knock down of the NOTCH1 gene, there were no
differences among the NOTCH1 pathway and PI3K-PTEN-AKT/mTOR pathway proteins
in the control and treated samples of each cell line.
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Figure 12: Silencing NOTCH1 has no significant effect on the PI3K-PTENAKT/mTOR pathway.
Western blot analysis and quantification of NOTCH1 pathway and PI3K-PTENAKT/mTOR pathway protein levels after 20nM siRNA treatment for 24 hours in [A] FADU,
[B] PJ34, and [C] OSC19. Control and treated samples are denoted in blue and red,
respectively.
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3.6 Knockout (KO) of NOTCH1 leads to differential effects on the PI3K-PTENAKT/mTOR pathway
Using siRNA to silence the NOTCH1 gene successfully inhibited NOTCH1
signaling, but did not have a significant effect on HES1 or the PI3K-PTEN-AKT/mTOR
pathway. We decided to use a more specific genetic approach to prevent NOTCH1
signaling. We received FADU and PJ34 Crispr/Cas9-generated NOTCH1 KO cell lines
from Dr. Mitchell Frederick’s laboratory. Because both alleles of NOTCH1 are stably
deleted from both cell lines, we resolved this method of blocking NOTCH1 signaling to
be the most efficient method of inhibition. We cultured the respective cell lines for 24
hours, collected lysate, and measured the NOTCH1 pathway and PI3K-PTENAKT/mTOR pathway proteins via western blot analysis. Cells in the control group were
transfected with an empty vector. Experiments were repeated twice in each cell line for
validity and reliability measures (n=2).
We proposed that genetically deleting both alleles of NOTCH1 would effectively
prevent NOTCH1 signaling, leading to markedly increased PTEN activity and the
subsequent inactivation of the PI3K-PTEN-AKT/mTOR pathway. Strikingly, the results
were cell-line-specific. While both Crispr/Cas9-generated NOTCH1 KO cell lines
successfully inhibited NOTCH1 signaling, as confirmed by the absence of NOTCH1 and
NICD protein, the effect on the PI3K-PTEN-AKT/mTOR pathway was different in each
cell line. Although the NOTCH1 KO treatment led to inactivation of the PI3K-PTENAKT/mTOR pathway in FADU, it led to activation of the pathway in PJ34 (Figure 13). The
results are irrespective of the HES1 and PTEN protein levels, which were not affected
by the NOTCH1 KO treatment, in each cell line. The data further confirms the observation
that the NOTCH1-HES1-PTEN interaction in T-ALL may be weak or nonexistent in
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HNSCC. The data also suggests that if there is a link between the NOTCH1 and PI3KPTEN-AKT/mTOR pathways in HNSCC, it may vary across the cell lines.
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Figure 13: NOTCH1-/- leads to differential effects on the PI3K-PTEN-AKT/mTOR
pathway.
Western blot analysis and quantification of NOTCH1 pathway and PI3K-PTENAKT/mTOR pathway protein levels in [A] FADU and [B] PJ34 Crispr/Cas9-generated
NOTCH1 KO cell lines. Parental, control, and NOTCH1 KO samples are indicated by
blue, green, and red, respectively.
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3.7 Knockout (KO) of NOTCH1 leads to differential effects on HES1 and PTEN
transcription in HNSCC
The Crispr/Cas9-generated deletion of both alleles of NOTCH1 proved to be the
most effective method of inhibiting NOTCH1 signaling. As a result, we sought to explore
the effect of this method of inhibition on the transcription of HES1 and PTEN in HNSCC.
We cultured FADU and PJ34 Crispr/Cas9-generated NOTCH1 KO cell lines for 24 hours,
isolated RNA, and measured NOTCH1, HES1, and PTEN mRNA levels via qRT-PCR.
Cells in the control group were transfected with an empty vector. Experiments were
repeated twice in each cell line for validity and reliability measures (n=2).
Based on the well-known NOTCH1-HES-PTEN association in T-ALL, we
postulated that the Crispr/Cas9-mediated inhibition of NOTCH1 signaling would
significantly decrease HES1 transcription and greatly increase PTEN transcription. The
findings displayed in Figure 14 show that Crispr/Cas9-mediated inhibition of NOTCH1
signaling significantly downregulates HES1 transcription but has no significant effect on
PTEN transcription in both cell lines. The data is promising because it supports the
premise of the central hypothesis, which holds that HES1 transcription is regulated by
the NOTCH1 pathway. Additionally, the results of the western blot and qRT-PCR
analyses in the Crispr/Cas9-generated NOTCH1 KO cell lines are the only evidence that
an interaction between the NOTCH1 pathway and the PI3K-PTEN-AKTmTOR pathway
exists in HNSCC. Although the mediators of communication between the pathways in
HNSCC may differ from those in T-ALL, the data suggests that an interaction between
the pathways is present in HNSCC.
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Figure 14: NOTCH1-/- has differential effects on HES1 and PTEN transcription in
HNSCC.
Quantification of NOTCH1, HES1, and PTEN mRNA levels after qRT-PCR analysis of
[A] FADU and [B] PJ34 Crispr/Cas9-generated NOTCH1 KO cell lines. Parental and
NOTCH1 KO samples are indicated by blue and red, respectively.
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3.8 Restoration of NOTCH1 signaling has no significant effect on the PI3K-PTENAKT/mTOR pathway in HNSCC
Because the results of the western blot and qRT-PCR analyses in the
Crispr/Cas9-generated NOTCH1 KO cell lines were in accordance with our central
hypothesis, we sought to validate the findings by restoring active NOTCH1 signaling in
the NOTCH1 KO cell lines. Dr. Mitchell Frederick’s laboratory also developed FADU and
PJ34 Crispr/Cas9-generated NOTCH1 KO cell lines that expressed a doxycyclineinducible Notch1 intracellular domain (NICD) system. Simply put, the inducible NICD
system allowed us to restore active NOTCH1 signaling in the NOTCH1 KO cell lines,
which are entirely deficient of any NOTCH1 signaling capabilities. We treated both cell
lines with 100ng/ml of doxycycline for 24 hours. We then collected lysate and measured
NOTCH1 pathway and PI3K-PTEN-AKT/mTOR pathway protein levels via western blot
analysis. Experiments were repeated twice in each cell line for validity and reliability
measures (n=2).
We expected that restoring active NOTCH1 signaling in the NOTCH1 KO cell lines
would yield an effect on the PI3K-PTEN-AKT/mTOR pathway that was the opposite of
what was exhibited in the Crispr/Cas9-mediated inhibition of NOTCH1 signaling.
Restoring NOTCH1 signaling would upregulate HES1 transcription and downregulate
PTEN activity, resulting in the hyper-activation of the PI3K/AKT/mTOR pathway.
However, restoring NOTCH1 signaling had no significant effect on HES1 or the PI3KPTEN-AKT/mTOR pathway in either cell line (Figure 15). There were no consistent or
significant differences among the pathway proteins in the control and treated samples of
each of the cell lines. The data offers a strong rationale for moving further along the
NOTCH1 pathway and focusing on the manipulation of HES1 to investigate the
interaction between the NOTCH1 and the PI3K-PTEN-AKT/mTOR pathways.
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Figure 15: Restoring NOTCH1 signaling has no significant effect on the PI3KPTEN-AKT/mTOR pathway in HNSCC.
Western blot analysis and quantification of NOTCH1 pathway and PI3K-PTENAKT/mTOR pathway protein levels in [A] FADU and [B] PJ34 Crispr/Cas9-generated
NOTCH1 KO cell lines transfected with the inducible NICD vector. Parental, control,
NOTCH1 KO, and NOTCH1 KO + iNICD samples are indicated by blue, green, red, and
purple, respectively.
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3.9 Knock down (KD) of HES1 has no significant effect on the PI3K-PTENAKT/mTOR pathway in HNSCC
According to the outcomes of previous experiments, we have concluded that
manipulating the NOTCH1 pathway does not have a significant or consistent effect on
the PI3K-PTEN-AKT/mTOR pathway in HNSCC. However, manipulating the pathway
has a minimal effect on HES1 protein levels in HNSCC. We postulate that manipulating
HES1 may affect PTEN transcription because HES1 is a more direct regulator of PTEN
and ultimately PI3K/AKT/mTOR pathway activity. We treated the 3 NOTCH1 wild-type
HNSCC cell lines (FADU, PJ34, and OSC19) with 20nM siRNA targeting the HES1 gene
for 24 hours. HES1 protein and mRNA have a half-life of approximately 20 minutes,
making 24 hours a suitable time point for silencing the HES1 gene (Kobayashi et al.,
2015). The control groups of the respective cell lines were treated with 20nM nontargeting siRNA for 24 hours. We then collected lysate and measured NOTCH1 pathway
and PI3K-PTEN-AKT/mTOR pathway protein levels via western blot analysis.
Experiments were repeated twice in each cell line for validity and reliability measures
(n=2).
Figure 16 reveals that silencing the HES1 gene has no significant effect on PTEN
or the PI3K/AKT/mTOR pathway in either of the cell lines. Taken together with the
experiments involved in manipulating NOTCH1 signaling, the data supports the
observation that the NOTCH1 pathway does not affect the PI3K-PTEN-AKT/mTOR
pathway in HNSCC. Given the unestablished NOTCH-HES1-PTEN association in
HNSCC, we should explore other potential mediators of communication between the
NOTCH1 pathway and the PI3K-PTEN-AKT/mTOR pathway in HNSCC (i.e. PTEN or
AKT).
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Figure 16: Silencing HES1 has no significant effect on the PI3K-PTEN-AKT/mTOR
pathway.
Western blot analysis and quantification of NOTCH1 pathway and PI3K-PTENAKT/mTOR pathway protein levels after 20nM siRNA treatment for 24 hours in [A] FADU,
[B] PJ34, and [C] OSC19. Control and treated samples are denoted in blue and red,
respectively.
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CHAPTER 4:
DISCUSSION & FUTURE DIRECTIONS
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4.1 Discussion
While the oncogenic role of NOTCH1 is well-established in T-ALL, the tumor
suppressive role of NOTCH1 in HNSCC is poorly understood. Preliminary studies in our
laboratory report that NOTCH1 mutant HNSCC cell lines are sensitive to dual
PI3K/mTOR inhibitors, suggesting a potential interaction between the NOTCH1 and
PI3K-PTEN-AKT/mTOR pathways in vivo. In T-ALL, the crosstalk between both
pathways has been heavily studied and is distinctively characterized in the literature. In
HNSCC, on the other hand, the interaction between both pathways is largely unknown
and remains the focus of most prominent research in the field. Although the findings of
many of the experiments in this research consist of negative data, we have been able to
formulate rather insightful conclusions regarding the interaction between the NOTCH1
and PI3K-PTEN-AKT/mTOR pathways in HNSCC.
We employed three methods of inhibition to block NOTCH1 signaling in NOTCH1
wild-type HNSCC cell lines, with each successive method being more specific in its
targeting potential than its predecessor. Using OMP-52M51 to block NOTCH1 signaling
had no significant effect on HES1 or the PI3K-PTEN-AKT/mTOR pathway at the protein
level. Additionally, silencing the NOTCH1 gene to block NOTCH1 signaling had no
significant effect on HES1 or the PI3K-PTEN-AKT/mTOR pathway at the protein level.
The findings of these experiments suggest the nonexistence of any type of interaction
between the NOTCH1 and PI3K-PTEN-AKT/mTOR pathways in HNSCC.
On the other hand, employing a more specific genetic method to prevent NOTCH1
signaling yielded more promising results. The Crispr/Cas9-mediated inhibition of
NOTCH1 signaling led to downregulated PI3K/AKT/mTOR activity in FADU and
upregulated PI3K/AKT/mTOR activity in PJ34. The findings restore our confidence in the
initial observation that a possible interaction exists between the NOTCH1 and PI3K71

PTEN-AKT/mTOR pathways in HNSCC. Nevertheless, the cell-line-specific findings
show that the pathways may be regulated differently across the cell lines. The findings
further suggest that the active domains of the NOTCH1 receptor must be completely
removed from the cell to effectively inhibit its signaling and observe any effects that
pathway inhibition may have on other pathways in the cell. Because the treatment had
no significant effect on the HES1 and PTEN protein levels of both cell lines, we can infer
that the potential crosstalk between both pathways is not mediated by either HES1 or
PTEN.
Restoring NOTCH1 signaling in NOTCH1 wild-type HNSCC cell lines had no
significant effect on HES1 or the PI3K-PTEN-AKT/mTOR pathway at the protein level,
imparting a fundamental indication that the link between both pathways may be a rather
weak link. However, qRT-PCR analysis following each method of inhibiting NOTCH1
signaling revealed that HES1 mRNA levels were significantly reduced after blocking
NOTCH1 signaling, but there was no effect on the PTEN mRNA levels. The findings
confirm that the NOTCH1-HES1 association present in T-ALL is also present in HNSCC.
Inactivating NOTCH1 signaling inhibits HES1 transcription, resulting in significantly
decreased HES1 mRNA levels. The results also suggest that the well-established
interaction between HES1 and PTEN in T-ALL is not present in HNSCC. Additionally,
silencing HES1 had no significant effect on PTEN or the PI3K/AKT/mTOR pathway at
the protein level, providing sufficient evidence that the link between HES1 and PTEN
does not exist in HNSCC. Taken together, the results of the experiments in this research
support the observation that an interaction does not exist between the NOTCH1 pathway
and the PI3K-PTEN-AKT/mTOR in HNSCC.
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4.2 Future Directions
The findings of this project provide valuable insight into understanding whether
the NOTCH1 and PI3K-PTEN-AKT/mTOR pathways communicate in HNSCC. The data
also imparts fundamental objectives for directing experimental efforts to identify potential
mediators of communication between both pathways. Establishing a distinct relationship
between NOTCH1, HES1 and PTEN in HNSCC cell lines is crucial to understanding how
the NOTCH1 and PI3K-PTEN-AKT/mTOR pathways communicate in HNSCC.
Unfortunately, the experimental efforts executed in this project did not succeed in
identifying the mechanism of crosstalk between both pathways.
Employing more specific genetic methods to manipulate target proteins will enable
us to study the effects of the respective treatments on pathway interactions. For instance,
utilizing Crispr/Cas9 methodologies to genetically delete both alleles of HES1 from the
cells may enable us to identify an association between HES1 and PTEN in HNSCC. We
will also consider the possibility of bidirectional crosstalk between the pathways in
HNSCC. To test our hypothesis, we will employ chemical and genetic methodologies to
manipulate each component of the PI3K-PTEN-AKT/mTOR pathway and measure the
effect the treatment has on the NOTCH1 pathway. Additionally, utilizing high throughput,
quantitative, functional proteomic and genomic technologies, such as reverse phase
protein array (RPPA) and RNA sequencing, will aid us in narrowing our search for more
specific mediators of communication between both pathways. Elucidating the potential
mechanisms of communication between the NOTCH1 and the PI3K-PTEN-AKT/mTOR
pathways presents both pathways as fundamental targeting agents for improving many
HNSCC targeted therapies.
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